|
Van Rijn lab (PI - Richard M. van Rijn PhD)
Purdue University, College of Pharmacy, Department of Medicinal Chemistry and Molecular Pharmacology The mission of the Van Rijn lab is to uncover new strategies to treat psychiatric and neurological disorders. We specifically investigate the heavily co-morbid triad of drug use disorders, chronic pain disorders and mood disorders. Our primary target, the delta opioid receptor, is involved in the neuropharmacology of all three disorders and thus offers an exciting novel approach to treat these disorders. The Van Rijn lab covers all aspects of preclinical drug development including drug synthesis, drug screening, pharmacological characterization both in vitro and in vivo. We also perform mechanistic studies to improve our understanding of the etiology of these disorders.
News - 2019February 4th. 2019 - Congratulations to Meridith Robins for getting her manuscript entitled "repeated use of the psychoactive substance ethylphenidate impacts neurochemistry and reward learning in adolescent male and female mice" accepted in Frontiers in Neuroscience. Also congratulations to co-authors Arryn Blaine and undergraduate Ellen Ha, and thanks to our collaborator Dr. Amy Brewster.
January 17th, 2019 - Congratulations to Anna Gutridge for receiving a travel award from ASPET to attend the 2019 meeting. January 11th, 2019 - Congratulations to Mee Jung Ko on her first author paper in collaboration with the Fai lab providing "Critical evaluation of TRPA1-mediated locomotive behavior in zebrafish as a screening tool for novel anti-nociceptive drug discovery." which has been accepted for publication in Scientific Reports. Arbaaz Mukadam is a co-author on this paper. This project was initiated by Mee Jung Ko and Logan Ganzen who received $2000 pilot funding from the Purdue Institute for Integrative Neuroscience. January 9th, 2019 - Anna Gutridge received a travel award from the Purdue Institute for Integrative Neuroscience to attend the 2019 ASPET meeting in Orlando to present her work on kratom in alcohol use disorder. January 3rd, 2019 - Purdue University made a press release highlighting our recent paper describing rubiscolin peptides as novel G-protein biased delta opioid receptor agonists, that have the potential to have in vivo efficacy in animal models of chronic pain, alcohol use disorder and mood disorders. January 2nd, 2019 - Dr. Marc Siegel mentioned the adenylyl cyclase 1 inhibitor, we helped characterize in vivo in a model for inflammatory pain as a medical innovation in an opinion piece on the Fox News website. Science trumps politics. Register.Vote. Help others to register and vote. Apathy leads to stupidity.
|
RECENT PUBLICATIONSFebruary 4th, 2019 - Our paper describing how repeated use of the psychoactive substance ethylphenidate impacts neurochemistry and reward learning in adolescent male and female mice has been accepted for publication in Frontiers in Neuroscience.
January 11th, 2019 - Our paper in collaboration with the Fai lab providing "Critical evaluation of TRPA1-mediated locomotive behavior in zebrafish as a screening tool for novel anti-nociceptive drug discovery." has been accepted for publication in Scientific Reports. December 16th, 2018 - Our paper describing our discovery that rubiscolins are naturally occurring G-protein-biased delta opioid receptor peptides has been accepted for publication in the journal European. Neuropsychopharmacology. November 15th, 2018 - A paper led by The Flaherty lab on which we collaborated titled "optimization of a 1,3,4-oxadiazole series for inhibition of Ca2+/calmodulin-stimulated activity of adenylyl cyclases 1 and 8 for the treatment of chronic pain" was accepted in European Journal of Medicinal Chemistry. November 8th, 2018 - Our review paper describing "arrestin recruitment and signaling by G protein-coupled receptor heteromers was accepted in a special issue of Neuropharmacology on "Brain heteroreceptor complexes in health and disease". March 18th, 2018 - Our paper investigating the role of Gi-protein activity in the dorsal striatum in modulating voluntary alcohol intake has been accepted for publication in the open access journal Frontiers in Psychiatry as part of the special topics in opioid research issue. March 1st, 2018 - Our paper characterizing beta-arrestin 1 knockout mice in anxiety-like and alcohol behavior has been accepted for publication in the open access journal Frontiers in Behavioral Neuroscience. November 30th, 2017 - A collaborative manuscript by visiting scientist Ricardo Marquez-Gomez describing evidence for the existence of heteromers between adenosine A2a and histamine H3 receptors has been accepted in the journal Pharmacological Research. FIND US HEREDisclaimer of opinion
The information, statements and opinions presented on the the Van Rijn lab website are solely expressed by Dr. van Rijn and do not necessarily represent views held by Purdue University. Donate to science.
If you appreciate the research carried out in the Van Rijn lab and support our goals feel free to donate to the advancement of science. Donations will be used to help support (undergraduate) students and carry out experiments exploring exciting new preliminary projects, currently not funded through other mechanisms. Donations can be made by specifically mentioning the Van Rijn lab at the following Purdue University website: Purdue Research Foundation: Giving to Purdue Instructions on types of donations |
Affiliations:
|
|